1-8 of 8
William G. Bornmann
Close
Sort by
Journal Articles

Small Molecule Inhibition of SIRT Activity: A Novel Therapeutic Approach for Acute Myeloid Leukemia

Steffan T Nawrocki, PhD, Claudia M Espitia, MS, Kevin R. Kelly, MD, William G. Bornmann, PhD, Jennifer S Carew, PhD
Journal: Blood
Blood (2011) 118 (21): 84.
https://doi.org/10.1182/blood.V118.21.84.84
Published: 2011
Journal Articles

Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis

Hanshi Sun, Vaibhav Kapuria, Luke F. Peterson, Dexing Fang, William G. Bornmann, Geoffrey Bartholomeusz, Moshe Talpaz, Nicholas J. Donato
Journal: Blood
Blood (2011) 117 (11): 3151–3162.
https://doi.org/10.1182/blood-2010-03-276477
Published: 2011
Includes: Supplemental data
Journal Articles

Pharmacological Inhibition of Fatty Acid Oxidation as a Novel Therapeutic Concept for Acute Myeloid Leukemia.

Michael Andreeff, MD, PhD, Michael Fiegl, PhD, Marina Konopleva, MD, PhD, Borys Korchin, Kumar Kaluarachchi, PhD, William G. Bornmann, PhD, Patrick H. Guthrie, BS, Romain Harmancey, PhD, Heinrich Taegtmeyer, MD, PhD, Ismael J. Samudio, PhD
Journal: Blood
Blood (2009) 114 (22): 3779.
https://doi.org/10.1182/blood.V114.22.3779.3779
Published: 2009
Journal Articles

WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells.

Nicholas J Donato, Ph.D., Hanshi Sun, Ph.D., Vaibhav Kapuria, Luke F Peterson, PhD, Geoffrey Bartholomeusz, Ph.D., William G. Bornmann, Ph.D., Moshe Talpaz, M.D.
Journal: Blood
Blood (2009) 114 (22): 3303.
https://doi.org/10.1182/blood.V114.22.3303.3303
Published: 2009
Journal Articles

Structure-Based Drug Design of c-Kit Inhibitors for Use in the Treatment of Acute Myeloid Leukemia.

David S. Maxwell, PhD, Ashutosh Pal, Zhenghong Peng, Alexandr Shavrin, Stefan Faderl, MD, David Harris, Quin Van, Zhiming Liu, Srdan Verstovsek, MD PhD, Taghi Manshouri, MB BS, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, MD, Zeev Estrov, MD, William G. Bornmann, PhD
Journal: Blood
Blood (2006) 108 (11): 1906.
https://doi.org/10.1182/blood.V108.11.1906.1906
Published: 2006
Journal Articles

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia

Nicholas C. Wolff, Darren R. Veach, William P. Tong, William G. Bornmann, Bayard Clarkson, Robert L. Ilaria, Jr
Journal: Blood
Blood (2005) 105 (10): 3995–4003.
https://doi.org/10.1182/blood-2004-09-3534
Published: 2005
Journal Articles

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor

Nikolas von Bubnoff, Darren R. Veach, Heiko van der Kuip, Walter E. Aulitzky, Jana Sänger, Petra Seipel, William G. Bornmann, Christian Peschel, Bayard Clarkson, Justus Duyster
Journal: Blood
Blood (2005) 105 (4): 1652–1659.
https://doi.org/10.1182/blood-2004-06-2445
Published: 2005
Journal Articles

A Cell-Based Screening Method for Resistance of Bcr-Abl Positive Leukemia Identifies the Mutation Pattern for an Alternative Abl Kinase Inhibitor.

Nikolas von Bubnoff, M.D., Darren R. Veach, Ph.D., Heiko van der Kuip, Ph.D., Walter E. Aulitzky, M.D., Jana Saenger, Petra Seipel, William G. Bornmann, Ph.D., Christian Peschel, M.D., Bayard Clarkson, M.D., Justus Duyster, M.D.
Journal: Blood
Blood (2004) 104 (11): 558.
https://doi.org/10.1182/blood.V104.11.558.558
Published: 2004